Soberana 02 - Wikipedia

/Soberana_02

  • A small island nation has cooked up not 1, not 2 but 5 COVID vaccin...
    https://diasp.eu/p/14073484

    A small island nation has cooked up not 1, not 2 but 5 COVID vaccines. It’s Cuba!

    Cuba has one of the world’s highest COVID vaccination rates, with more than 85% of the nation fully immunized and kids as young as 2 getting inoculated. And it’s done so using homegrown vaccines.

    #news #npr #publicradio #usa posted by pod_feeder_v2

    • propre lien :

      https://www.npr.org/sections/goatsandsoda/2022/02/01/1056952488/a-small-island-nation-has-cooked-up-not-1-not-2-but-5-covid-vaccines-its-cuba

      [...]

      Cuba’s success in developing COVID vaccine at a pace on par with some of the world’s largest pharmaceutical companies may seem surprising. The country has been in economic and social turmoil. It’s been facing shortages of food, fuel and foreign currency, that sparked major street protests last summer. Pandemic lockdowns further battered the economy, depriving the country of one of it’s largest sources of revenue- tourism. U.S. President Trump in his final days in office, ramped up sanctions against the communist island, making it even harder for Cuba to import raw materials and pharmaceutical manufacturing equipment. But William LeoGrande, a professor of government at American University in Washington, D.C. who’s written extensively about Cuba, wasn’t surprised that Cuba’s bet on a domestic vaccine paid off. LeoGrande says many people in the U.S. often underestimate the sophistication of the Cuban biotech industry.

      “The reason is because there are large sectors of the Cuban economy that really don’t work very well,” he says. “And so the image that that creates here in the United States is that nothing works in Cuba. But the reality is that there are some sectors and biotechnology is one of them that work pretty well.”

      LeoGrande says Cuba’s rapid development of 5 COVID vaccines was a major coup for the Caribbean nation.

      “Cuba was able to vaccinate virtually the entire population without having to worry about access to foreign vaccines while most of the Third World is not yet vaccinated because the vaccines are all produced in the developed countries,” he says. “And finally, Cuba may be able to generate some revenue by selling the vaccines to other developing countries at a time when it is really in desperate need of foreign exchange currency.”

      One potential stumbling block for exporting Cuban COVID vaccines is that hasn’t made progress in getting regulatory authorization for the products from the WHO. Individual countries are still welcome to authorize the shots locally if they so wish but a stamp of approval from WHO or another major regulator would make it far easier for Cuba to export these medical products.

      Cuba has submitted Soberana 1, Soberana 2, Soberana Plus and Abdala for Emergency Use Listing by the WHO but their application hasn’t moved forward. Notes on the WHO’s website tracking the status of vaccine applications says that the regulatory body is still “awaiting information on strategy and timelines for submission” regarding the communist nation’s COVID vaccines.

      [...]

      #Cuba #vaccins #covid #biotechnologie

    • Vaccin #Soberana 02

      https://en.wikipedia.org/wiki/Soberana_02#Efficacy

      [...]

      Efficacy

      The interim results of a Phase III trial in Cuba has shown an efficacy of 62% after only two doses.[9][10][11] Two-dose vaccine efficacy of 62% against symptomatic disease was attained “during predominant transmission of the beta VOC.”[12] When combined with a booster dose of Soberana Plus, the vaccine showed an efficacy of 91.2%,[13] according to BioCubaFarma.

      The interim results of the Phase III trial in Iran show that the efficacy of a two-dose regimen is 51.31% against symptomatic disease, 78.35% against severe disease, and 76.78% against hospitalization.[14][15] A third dose of Soberana Plus increases the efficacy against symptomatic disease to 70.58%, 83.52% against severe disease, and 91.76% against hospitalization.[14] 89% of the cases in the Iranian trial were identified as having the delta strain.[15]

      The final results of the Phase III trials in Cuba show an efficacy against symptomatic disease of 71.0% against the beta and delta strains, while a third dose of Soberana Plus increased the efficacy up to 92.4%.[12] Efficacy against severe disease and death is 100% for the heterologous three-dose regimen.[16]

      The final results of the Phase III trial in Iran show an efficacy of 67% against symptomatic disease and 96.5% against severe disease and hospitalization for a heterologous three-dose regimen.[17][18] No deaths were observed in the trial group that received the three-dose regimen.[19] Unlike the Phase III trials in Cuba,[12] the majority of cases throughout the entire trial were of the delta strain (more than 90% at the time of vaccine evaluation).[20]

      [...]